Accumulation of MDM2 in pleomorphic xanthoastrocytomas

Pathology International

Volumn 54, Issue 6, 2004, Pages 387-391

  Matsumoto, Kenichi ^a   Suzuki, Satoshi O ^a   Fukui, Masashi ^a   Iwaki, Toru ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; mdm2; Molecular genetics; p53; Pleomorphic xanthoastrocytoma

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MALE; PLEOMORPHIC XANTHOASTROCYTOMA; PRIORITY JOURNAL; REGULATORY MECHANISM;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042651137     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01637.x     Document Type: Article

References (35)

1. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma. A distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 1979; 44: 1839-52.
2. Kepes JJ. Pleomorphic xanthoastrocytoma. The birth of a diagnosis and a concept. Brain Pathol 1993; 3: 269-74.
3. Iwaki T, Fukui M, Kondo A, Matsushima T, Takeshita I. Epithelial properties of pleomorphic xanthoastrocytomas determined in ultrastructural and immunohistochemical studies. Acta Neuropathol 1987; 74: 142-50.
4. Kepes JJ, Louis DN, Giannini C, Paulus W. Pleomorphic xanthoastrocytoma. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumors of the Central Nervous System. Lyon: IARC/WHO, 2000; 52-4.
5. Palma L, Maleci A, Di Lorenzo N, Lauro GM. Pleomorphic xanthoastrocytoma with 18-year survival: case report. J Neurosurg 1985; 63: 808-10.
6. Gaskill SJ, Marlin AE, Saldivar V. Glioblastoma multiforme masquerading as a pleomorphic xanthoastrocytoma. Childs Nerv Syst 1988; 4: 237-40.
7. Macaulay RJ, Jay V, Hoffman HJ, Becker LE. Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma. Case report. J Neurosurg 1993; 79: 761-8.
8. Bayindir C, Balak N, Karasu A, Kasaroglu D. Anaplastic pleomorphic xanthoastrocytoma. Childs Nerv Syst 1997; 13: 50-56.
9. Bucciero A, De Caro MI, Tedeschi E et al. Atypical pleomorphic xanthoastrocytoma. J Neurosurg Sci 1998; 42: 153-7.
10. Charbel FT. Pleomorphic xanthoastrocytoma with malignant progression. Surg Neurol 1998; 50: 385-6.
11. Prayson RA, Morris HH 3rd. Anaplastic pleomorphic xanthoastrocytoma. Arch Pathol Lab Med 1998; 122: 1082-6.
12. Chakrabarty A, Mitchell P, Bridges LR, Franks AJ. Malignant transformation in pleomorphic xanthoastroytoma. A report of two cases. Br J Neurosurg 1999; 13: 516-19.
13. Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics 2001; 3: 159-62.
14. Lang FF, Miler DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994; 9: 949-54.
15. Korkolopoulou P, Christodoulou P, Kouzelis K et al. MDM2 and p53 expression in gliomas. A multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997; 75: 1269-78.
16. Rainov NG, Dobberstein KU, Bahn H et al. Prognostic factors in malignant glioma, influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro Oncol 1997; 35: 13-28.
17. Newcomb EW, Cohen H, Lee SR et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, 53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998; 8: 655-67.
18. Haga S, Morioka T, Nishio S, Fukui M. Multicentric pleomorphic xanthoastrocytomas. Case report. Neurosurgery 1996; 38: 1242-5.
19. Miyagi Y, Suzuki SO, Iwaki T et al. Pleomorphic xanthoastrocytoma with predominantly exophytic growth. Case report. Surg Neurol 2001; 56: 330-32.
20. Suzuki SO, Iwaki T. Amplification and overexpression of mdm2 gene in ependymomas. Mod Pathol 2000; 13: 548-53.
21. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR of the detection of EGFR and MDM2 gene amplification in DNA ectracted from FFPE glioma tissue. J Neuropathol Exp Neurol 1995; 54: 57-64.
22. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
23. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 auto-regulatory feedback loop. Genes Dev 1993; 7: 1126-32.
24. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
25. Kubbutat M, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997; 387: 299-303.
26. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
27. Watanabe T, Hotta T, Ichikawa A et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158-65.
28. Capoulade C, Bressac-de Paillerets B, Lefrere I et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998; 16: 1603-10.
29. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.
30. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas, preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994; 54: 4299-303.
31. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H. Amplification and overexpression of mdm2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997; 56: 180-85.
32. Paulus W, Lisle DK, Tonn JC et al. Molecular genetic alterations in pleomorphic xanthoastrocytoma. Acta Neuropathol 1996; 91: 293-7.
33. Rostomily RC, Hoyt JW, Berger MS et al. Pleomorphic xanthoastrocytoma. DNA flow cytometry and outcome analysis of 12 patients. Cancer 1997; 80: 2141-50.
34. Giannini C, Scheithauer BW, Burger PC et al. Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 1999; 85: 2033-45.
35. Yin XL, Hui AB, Liong EC, Ding EC, Chang AR, Ng HK. Genetic imbalances in pleomorphic xanthoastrocytoma detected by comparative genomic hybridization and literature review. Cancer Genet Cytogenet 2002; 132: 14-19.